Overview

A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [C]Enlicitide Chloride ([C]MK-0616) in Healthy Participants (MK-0616-016)

Status:
COMPLETED

Trial end date:
2023-08-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn what happens to enlicitide chloride labeled with \[C\] in a person's body over time. A label can be added to a study medicine to trace it in a person's body.

Phase:

PHASE1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

MK-0616